 The need for NNRTIs with better resistance profile led to the development of the next generation of NNRTIs.Researchers at Janssens Foundation and Tibotec discovered the first drug in this class, etravirine, which was approved by the FDA in 2008.The second drug in this class, rilpivirine, was also discovered by Tibotec and was approved by the FDA in 2011.